JonathanDSchwartzMD

PubMed

• 7 citations
  Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes
  Julián Sevilla, Susana Navarro, Paula Río, Rebeca Sanchez-Dominguez, Josune Zubicaray, Eva M. Galvez, Eva Merino, Elena Sebastián, Carmen Azqueta, José A. Casado, José...> ;Molecular Therapy. Methods & Clinical Development. 2021 Sep 10
• 3 citations
  Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment.
  Susana Navarro, Oscar Quintana-Bustamante, Rebeca Sanchez-Dominguez, Sergio López-Manzaneda, Isabel Ojeda-Perez, Aída Garcia-Torralba, Omaira Alberquilla, Kenneth Law,...> ;Molecular Therapy. Methods & Clinical Development. 2021 Sep 10
• 10 citations
  Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients.
  María José Ramírez, Roser Pujol, Juan Pablo Trujillo-Quintero, Jordi Minguillón, Massimo Bogliolo, Paula Río, Susana Navarro, José A. Casado, Isabel Badell, Estela Car...> ;American Journal of Hematology. 2021 Aug 1
• 4 citations
  Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal.
  Ilana Moscatelli, Elena Almarza, Axel Schambach, David Ricks, Ansgar Schulz, Christopher D. Herzog, Kim Henriksen, Maria Askmyr, Jonathan D. Schwartz, Johan Richter> ;Molecular Therapy. Methods & Clinical Development. 2021 Mar 12
• 40 citations
  Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease
  Ana Maria Manso, Sherin Hashem, Bradley C. Nelson, Emily Gault, Angel Soto-Hermida, Elizza Villarruel, Michela Brambatti, Julius Bogomolovas, Paul J. Bushway, Chao Che...> ;Science Translational Medicine. 2020 Mar 18
• 23 citations
  Mosaicism in Fanconi anemia: concise review and evaluation of published cases with focus on clinical course of blood count normalization
  Eileen Nicoletti, Gayatri R Rao, Juan A. Bueren, Paula Río, Susana Navarro, Jordi Surrallés, Grace Choi, Jonathan D. Schwartz> ;Annals of Hematology. 2020 Feb 17
• 8 citations
  Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double...
  Harry H. Yoon, Johanna C. Bendell, Fadi Braiteh, Irfan Firdaus, Philip A. Philip, Allen Lee Cohn, Nancy L. Lewis, Edward Arrowsmith, Jonathan D. Schwartz, Ling Gao, Ya...> ;Annals of Oncology. 2019 Dec 1
• 96 citations
  Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia.
  Paula Río, Susana Navarro, Wei Wang, Rebeca Sanchez-Dominguez, Roser Pujol, José C. Segovia, Massimo Bogliolo, Eva Merino, Ning Wu, R Salgado, María L. Lamana, Rosa Ya...> ;Nature Medicine. 2019 Sep 1
• 59 citations
  Leukocyte adhesion deficiency-I: A comprehensive review of all published cases.
  Elena Almarza Novoa, Sanchali Kasbekar, Adrian J. Thrasher, Donald B. Kohn, Julián Sevilla, Tony Nguyen, Jonathan D. Schwartz, Juan A. Bueren> ;The Journal of Allergy and Clinical Immunology. in Practice. 2018 Jul 1
• 25 citations
  A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretr...
  Maha Hussain, Dana E. Rathkopf, Glenn Liu, Andrew J. Armstrong, Wm. Kevin Kelly, Anna C. Ferrari, John D. Hainsworth, Adarsh Joshi, Rebecca R. Hozak, Ling Yang, Jonath...> ;European Journal of Cancer. 2015 Sep 1
• 619 citations
  Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH): A Randomise...
  Andrew X. Zhu, Joon Oh Park, Baek Yeol Ryoo, Chia Jui Yen, Ronnie T.P. Poon, Davide Pastorelli, Jean-Frédéric Blanc, Hyun Cheol Chung, Ari David Baron, Tulio Eduardo F...> ;The Lancet. Oncology. 2015 Jul 1
• 52 citations
  Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in...
  E.G. Chiorean, Herbert Hurwitz, Roger B. Cohen, Jonathan D. Schwartz, R.P. Dalal, F.E. Fox, Ling Gao, Christopher Sweeney> ;Annals of Oncology. 2015 Mar 18
• 13 citations
  Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor...
  Celestia S. Higano, Jordan Berlin, Michael S. Gordon, Patricia LoRusso, Shande Tang, Aruna Dontabhaktuni, Jonathan D. Schwartz, Jan Cosaert, Janice M. Mehnert> ;Investigational New Drugs. 2015 Mar 7
• 1578 citations
  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW)...
  Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae You Kim, David Cunn...> ;The Lancet. Oncology. 2014 Oct 1
• 22 citations
  A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
  Richard T. Penson, Kathleen M. Moore, Gini F. Fleming, Patricia S. Braly, Veronica L. Schimp, Hoa Nguyen, Ursula A. Matulonis, Susana Banerjee, Paul Haluska, Martin Go...> ;Gynecologic Oncology. 2014 Sep 1
• 17 citations
  A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.
  Richard D. Carvajal, Michael K. Wong, John A. Thompson, Michael S. Gordon, Karl D. Lewis, Anna C. Pavlick, Patrick B. Rojas, Jonathan D. Schwartz, Agop Y. Bedikian> ;European Journal of Cancer. 2014 Aug 1
• 25 citations
  A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor the...
  Jorge A. Garcia, Gary R. Hudes, Toni K. Choueiri, Walter M. Stadler, Laura S. Wood, Jayne Gurtler, Shailender Bhatia, Adarsh Joshi, Rebecca R. Hozak, Yihuan Xu, Jonath...> ;Cancer. 2014 Jun 1
• 45 citations
  An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer
  Rocio Garcia-Carbonero, Fernando Rivera, Joan Maurel, Jean-Pierre M. Ayoub, Malcolm J. Moore, Andrés Cervantes, Timothy R. Asmis, Jonathan D. Schwartz, F. Nasroulah, S...> ;The Oncologist. 2014 Apr 1
• 1495 citations
  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, plac...
  Charles S. Fuchs, Jiri Tomasek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira dos Santos, G. Aprile, David Ferry, Boh...> ;Lancet. 2014 Jan 4
• 121 citations
  A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocel...
  Andrew X. Zhu, Richard S. Finn, Mary F. Mulcahy, Jayne Gurtler, Weijing Sun, Jonathan D. Schwartz, Rita P. Dalal, Adarsh Joshi, Rebecca R. Hozak, Yihuan Xu, Marek Ancu...> ;Clinical Cancer Research. 2013 Dec 1
• 12 citations
  Segmental testicular infarction: sonographic findings and pathologic correlation.
  Michael Aquino, Hanh Nghiem, Syed Zafar Jafri, John Schwartz, Rajwant Malhotra, Mitual Amin> ;Journal of Ultrasound in Medicine. 2013 Feb 1
• 22 citations
  Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers.
  Eric K. Rowinsky, Jonathan D. Schwartz, Naseem Zojwalla, Hagop Youssoufian, Floyd Fox, Philippe Pultar, Ruslan Novosyadlyy, Jan Cosaert, Dale L. Ludwig> ;Current Drug Targets. 2011 Nov 30
• 16 citations
  Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
  Inga J. Duignan, Erik Corcoran, Anthony Pennello, Mary Jane Plym, Michael Amatulli, Nidia Claros, Michelle D. Iacolina, Hagop Youssoufian, Larry Witte, Selda Samakoglu...> ;Neoplasia. 2011 Jan 1
• 112 citations
  Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refrac...
  Diane Lauren Reidy, Efsevia Vakiani, Muhammad Wasif Saif, J. R. Hecht, Noah Goodman-Davis, Ellen Hollywood, Jinru Shia, Jonathan D. Schwartz, Kumari Chandrawansa, Arun...> ;Journal of Clinical Oncology. 2010 Sep 20
• 48 citations
  Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α
  Gaurav D. Shah, Nick Loizos, Hagop Youssoufian, Jonathan D. Schwartz, Eric K. Rowinsky> ;Cancer. 2010 Feb 15
• Join now to see all

Abstracts/Posters

• Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-Vivo FANCA Gene...
  Jonathan D Schwartz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Hematopoietic Engraftment of Fanconi Anemia Patients through 3 Years after Gene Therapy
  Jonathan D Schwartz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019